The current common practices involve the administration of EGFR-TKIs as first-line treatment to patients with EGFR-sensitive mutations because these drugs have been shown to considerably prolong progression-free survival while causing fewer adverse effects than chemotherapy [9].EGFR-TKIs have also been approved as the second- or third-line treatment for EGFR wild-type (EGFR-WT) NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.